Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches [Seeking Alpha]
GENFIT S.A. - American Depositary Shares (GNFT)
Company Research
Source: Seeking Alpha
Summary NASH is a common disease with an expected market size of 20 Bn. $ in 2030 and currently no approved drugs. A handful of companies including most of big pharma are in the NASH race to become early market entrants. Crucial phase III read-out of Genfit's lead candidate in NASH (Elafibranor) expected in a matter of weeks. If proven effective Elafibranor will become the first drug on the market against NASH resolution and the first suitable backbone therapy. Near-term upside of 650% can be unlocked by a big pharma acquisition. Potential acquirers are identified below. Introduction It is remarkable how few articles have been published about Genfit ( GNFT) June August delays disappointing results Genfit’s Elafibranor Genfit is trying to bring its lead product, Elafibranor, to market in several indications including NASH (Non-Alcoholic Steatohepatitis). NASH is a very common disease and will soon become the biggest cause for liver transplantation multiple metabolic methods of action o
Show less
Read more
Impact Snapshot
Event Time:
GNFT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNFT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNFT alerts
High impacting GENFIT S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GNFT
News
- Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus [Yahoo! Finance]Yahoo! Finance
- GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 [Yahoo! Finance]Yahoo! Finance
- GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024GlobeNewswire
- GENFIT Reports Third Quarter 2024 Financial Information [Yahoo! Finance]Yahoo! Finance
- GENFIT Reports Third Quarter 2024 Financial InformationGlobeNewswire